In a study published in Nature Communications, Dr. Muhammed Murtaza, who holds a joint appointment at Mayo Clinic and Translational Genomics Research Institute (TGEN), and colleagues, describe an extensive comparison between biopsy results and analysis of ctDNA in a patient with breast cancer.
In the following video, Dr. Murtaza describes how circulating tumor DNA in blood could inform physicians on best treatments for individual patients.
For more information, visit:
►Mayo Clinic Center for Individualized Medicine: http://mayoresearch.mayo.edu/center-for-individualized-medicine/?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Over the past decade, numerous studies have shown that many Americans have low vitamin D levels and as a result, vitamin D supplement use has climbed in recent years. Vitamin D has been shown to boost bone health and it may play a role in preventing diabetes, cancer, cardiovascular disease and other illnesses. In light of the increased use of vitamin D supplements, Mayo Clinic researchers set out to learn more about the health of those with high vitamin D levels. They found that toxic levels are actually rare.
Their study appears in the May issue of Mayo Clinic Proceedings. For more information, see the Mayo Clinic News Network: http://newsnetwork.mayoclinic.org/
There are hundreds of thousands of patients in the United States with end stage lung disease. Many of them are not candidates for lung transplantation or other therapies. Learn now lung regeneration, through the use of existing cells to build an artificial lung, is building a brighter future for patients with few treatment options.
To request an appointment, visit http://www.mayoclinic.org/departments-centers/transplant-center/lung-transplant/choosing-mayo-clinic/appointments-referrals?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Nicole Dehn, 30, has had epileptic seizures since she was six months old. Despite various medications and devices, her seizures remained uncontrolled. That is until Mayo Clinic offered hope with a new minimally invasive surgery. Known as laser thermal ablation, the therapy was previously approved by the U.S. Food and Drug Administration for treatment of tumors in other parts of the body, and is now being used for epilepsy patients. Early results are promising as Nicole is finally able to drive.
Jonathan Finnoff, D.O., Medical Director for Mayo Clinic Square, Sports Medicine Center, Minneapolis, Minnesota discusses the services they provide in their program. Sports performance training, psychology, trainers for individuals and teams. Rehabilitation services with physical therapists who are specialized in sports medicine. Orthopedic surgeons and physiatrists with sports medicine training are also available. The center includes on-site musculoskeletal ultrasound, the Exos sports performance program and a regenerative medicine program. Mayo Clinic Square is ready to help athletes of all ages and levels of ability.
In the United States, two-thirds of the population is said to be either overweight or obese. Now there’s a new option for those who might need medical help to lose weight but don’t qualify for weight loss surgery. This week Mayo Clinic surgeons were the first in the U.S. to implant a new device recently approved by the FDA. The procedure involves the temporary placement of a special balloon in the stomach and has the potential for lasting results. Here’s Dennis Douda for the Mayo Clinic News Network.
A promising new study from Mayo Clinic, in conjunction with Caris Life Sciences, points to immunotherapy as a possible treatment option for patients with the difficult-to-treat triple negative breast cancer mutation. The study was presented this week at the 50th annual meeting of the American Society of Clinical Oncology in Chicago.
“This study may change our ability to treat triple negative breast cancer patients,” says Barbara Pockaj, M.D., lead investigator of the study and Mayo Clinic surgeon. “We may have signs that these patients can be treated with immunotherapy. We don’t have a lot of options for these patients and this would really expand our options.”
It all began with a country doctor and his sons—two boys raised to be doctors “the way farm boys are taught to be farmers.”
This film imagines Dr. William J. Mayo recalling an actual event from his childhood, when he and his brother, Charlie, accompanied their father on a journey to perform a difficult operation. On that memorable day, Will and Charlie learned the values of compassion, teamwork and dedication to the needs of the patient – values that became the foundation of Mayo Clinic.
Mayo Clinic Heritage Films produces original documentaries and dramatizations about key aspects of Mayo’s history. With the generous support of our benefactors, these award-winning films include cinematography of the highest quality; rare photos, movies and artifacts; and interviews with people who took part in historic events.
Enjoy these preview clips and visit http://store.mayoclinic.com/productList.cfm?mpc=6 to purchase the full-length DVD. Proceeds from the sale of each film support Mayo’s not-for-profit mission of excellence in patient care, research and education.
Stroke is the leading cause of permanent disability in the U.S., striking nearly 800,000 people each year. Hemorrhagic, or bleeding, stroke is particularly devastating says Mayo Clinic neurologist and critical care expert Dr. William D. Freeman. “About 40 percent of hemorrhagic stroke patients die within a month, and half of the survivors have some type of impairment,” he adds.
Leo J. Maguire, M.D., consultant in cornea and external disease, developed the curriculum in resident corneal surgery at Mayo Clinic. In this series of videos, he discusses how to engineer the placement of a suture in a corneal transplant so that the length, depth, and radiality of the sutures are consistent around the circumference of a corneal graft. Mayo has used this methodology successfully with its Ophthalmology residents for the past 15 years.
A new drug, Ocrevus (ocrelizumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat multiple sclerosis (MS). The National Multiple Sclerosis Society says it’s a “game changer” and Mayo Clinic neurologist Dr. Dean Wingerchuk says, “The approval of ocrelizumab is an important milestone both for people with MS and MS research.”
In a news statement released Wed. March 29, Dr. Billy Dunn, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research says, “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”
More health and medical news on the Mayo Clinic News Network http://newsnetwork.mayoclinic.org/